High-priced drugs used to treat diabetic macular edema not cost-effective
Thursday, June 9, 2016 - 12:11
in Health & Medicine
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study.